Hotline: 86-023-62505954
 
 
R&D About us
Contact Us
/ contact us
If you want to consult products, call us:
TEL:
86-023-62505954
FAX:
86-023-62512066
E-mail:
cpri@cpri.com.cn

Generic product pipeline

 

TA

Drug

MOA

Indication

Status

ANDA

Cooperation

Opportunity

TUMOR

Afatinib

tablet

EGFR

tyrosine

kinase

inhibitors

Metastatic

non-small cell

lung cancer

IND filing

in China

 

OPEN

Veliparib

Capsule

PAR

inhibitor

Triple-negative

breast cancer

and metastatic

non-small cell

lung cancer

Process

R&D

 

 

OPEN

Lenvatin-

ibMesylate

Capsule

VEGFR

FGFR

PDGFR

Multiple

target

tyrosine

kinase

inhibitors

Thyroid cancer,

renal cell

carcinoma

and liver cancer

Process

R&D

 

 

 

OPEN

 

CVD

 

Rivarox-

aban tablet

 

Xa factor

inhibitor

 

Reduction Of

Risk Of Stroke

And Systemic

Embolism In

Nonvalvular

Atrial

Fibrillation

 

Treatment Of

Deep Vein

Thrombos is

Treatment Of

Pulmonary

Embolism

 

Reduction In

The Risk Of

Recurrence

Of Deep Vein

Thrombosis

And Of

Pulmonary

Embolism

 

Prophylaxis

Of Deep Vein

Thrombosis

Following Hip

Or Knee

Replacement

Surgery

Pre-MA

in China

 

 

 

 

 

 

 

 

 

 

 

 

 

 

OPEN for

International

Metabolic Disorders

Dapaglif-

lozin tablet

SGLT2

inhibitor

type

2 diabetes

IND filed

in China

OPEN or

International

Empaglif-

lozin tablet

SGLT2

inhibitor

type

2 diabetes

IND filed

in China

OPEN

Immu.

Apremilast

tablet

PDE4

inhibitor

Psoriatic

Arthritis or

Psoriasis

IND approved

in China

 

OPEN

Tofacitinib

citrateexte-

nded release

JAK1/JAK3

Tyrosine

protein

kinase

inhibitor

Rheumatoid

Arthritis

IND in China

 

 

OPEN

CK

Ferric

carboxyma-

ltose injection

sugar

polymer

releasing

iron

iron

deficiency

anemia

IND filing

in China

 

OPEN

Ferric

Citrate Tablet

Phosphate

binder

control

of serum

phosphorus

levels

IND filing

in China

 

OPEN

CNS

Safinamide

tablet

Reversible

monoamine

oxidase

inhibitor

Advanced PD

Process

R&D

 

OPEN

rivastigmine

transdermal

patch

Acetylchol-

inesterase

inhibitors

Alzheimer's

Disease

 

Parkinson's

Disease

Dementia

Process

R&D

 

 

OPEN

Pimavans-

erin tablet

5-HT2a

inverse

agonist

hallucinations

and delusions

associated

with Parkinson's

disease

psychosis

Process

R&D

 

 

OPEN

aripipra-

zolelauroxil

Sustain-

edrelease

injection

suspension

5-HT 2A

receptor

inhibitors,

5-HT 1a and

dopamine

D2 partial

agonists

schizophrenia

Process

R&D

 

 

 

OPEN

Brexpipra-

zole tablet

Partial

activation

of dopamine

D2 and

5-HT

receptors

major

depressive

disorder

Process

R&D

 

 

OPEN

Vortioxetine

tablet

5-HT

subtype

receptor

antagonists

and partial

agonists

major

depressive

disorder

Process

R&D

 

 

OPEN

Brivaraceta

tablet

High

efficient

selective

binding

of synaptic

vesicle

protein

2A(SV2A)

adjunctive

therapy in the

treatment of

partial-onset

seizures in

patients 16

years of age

and older

with epilepsy.

Process

R&D

 

 

 

 

OPEN

Pregab-

alin capsule

Gamma

aminobutyric

acid (GABA)

receptor

agonist

Management of

neuropathic pain

associated

with diabetic

peripheral

neuropathy

 

Management

of postherpetic

neuralgia

Adjunctive

therapy for

adult patients

with partial

onset seizures

 

Management of

fibromyalgia

 

Management of

neuropathic

pain associated

with spinal

cord injury

?

 

 

 

 

 

 

 

 

 

 

 

OPEN

Anesthesia

 

Remimazo-

lam injection

GABAA

receptor

agonist

Ultra short

acting sedative

anesthesia

Process

R&D

 

OPEN

Sugamma-

dex sodium

injection

GABAA

receptor

agonist

reversal of

neuromuscular

blockade

induced by

rocuronium

bromide

and vecuron-

iumbromide

inadults

undergoing

surgery.

Process

R&D

 

 

 

 

 

OPEN

Urinary

Oxybutynin

gel

M1, M2

and M3

muscarinic

receptor

antagonist

overactive

bladder with

symptoms

IND approved

in China

OPEN

Anti

Amoxicillin

Pulse release

tablets

Semisyn-

thetic

antibiotics

Streptococcus

pyogenes

and / or

pharyngitis

tonsillitis

IND approved

in China

 

 

OPEN

Delafloxacin

tablet and

injection

Broad-

spectrum

fluoroq-

uinolone

antibiotics

Acute bacterial

skin and

skin structure

infections

Process R&D

 

 

OPEN

ANDA R&D

 

 

 

 Contact Us
No.565 · NanAnDistrict · ChongQing
Tel: 86-023-62505954
86-023062505956
E-mail:cpri@cpri.com.cn
Copyright ©2005 - 2013 Chongqing Pharmaceutical Research Institute
犀牛云提供企业云服务